Novel treatment strategies for upper-tract urothelial cancer

DATE & PLACE
9 & 10 September 2022 (arrival on 8 September)


VENUE

Grand Majestic Hotel Prague
Prague, Czech Republic


REGISTRATION INFORMATION

Registration is obligatory for access to the expert meeting. Please register here.


LEARNING OBJECTIVES

After attending the meeting, participants should be able to:

  • Discuss measures to improve the diagnostic process for SMA at your clinic
  • Examine the evolving treatment landscape in SMA
  • Discuss practical considerations for the implementation of gene therapy
  • Develop individualized care plans for your patients with SMA, and explain how multidisciplinary management could be optimized
  • Outline measures for optimal integration of novel treatments and identify relevant criteria for patient selection


TARGET AUDIENCE

This meeting is intended for neurologists and neuromuscular disease specialists from Central and Eastern Europe and Israel who are responsible for the diagnosis and management of patients with SMA.


LANGUAGE

The official language of this educational meeting is English.


CONTACT

Should you have any questions about this educational meeting, please email Katrin.Zahlmann@ologyeducation.org.


SMA Expert Exchange: Novel treatments in clinical practice
is organized by Ology Medical Education, a global provider of independent medical education that develops CME initiatives for the international medical and scientific community.

Final programme to be announced prior to the meeting.


Thursday 8 September

Arrivals

18:30–21:30 Welcome dinner

 

Friday 9 September, 2022

09:00–09:20 Welcome lecture on current clinical practice in SMA
Jana Haberlová

Session 1: Improving the diagnostic process

09:20–09:50 Expert presentation and Q&A on the diagnosis of SMA
Aviva Fattal-Valevski
09:50–10:30 Small group activities/workshop sessions on diagnostic challenges and screening programmes
Moderated by the steering committee
10:30–10:50 Refreshment break
10:50–11:50 Group presentations and moderated discussion

Session 2: Implementing novel treatments

11:50–12:50 Expert presentation and Q&A on the evolving treatment landscape for SMA
Laurent Servais
12:50–13:50 Lunch break
13:50–14:50 Patient case presentations: gene therapy in clinical practice
Jana Haberlová, Katarzyna Kotulska, Aviva Fattal-Valevski
14:50–15:50 Small group activities/workshop sessions on the implementation of novel treatments
Moderated by the steering committee
15:50–16:10 Refreshment break
16:10–17:10 Group presentations and moderated discussion
17:10–18:10 Panel discussion about the implementation of novel treatments
Moderated by Jana Haberlová
Conclusions of the day
Katarzyna Kotulska
19:30-21:30 Dinner

 

Saturday 10 September, 2022

09:00-09:10 Overview of the programme for Day 2
Jana Haberlová

Session 3: Optimizing multidisciplinary care

09:10–09:50 Case-based expert presentation and Q&A on pulmonary care in SMA
Elaine Chan
09:50–10:30 Case-based expert presentation and Q&A on physiotherapy in SMA
Elena Mazzone
10:30–11:30 Small group activities/workshop sessions on multidisciplinary care in SMA
Moderated by the steering committee
11:30–11:50 Refreshment break
11:50–12:50 Group presentations and moderated discussion
12:50–13:00 Outlook on the future of SMA care
Jana Haberlová
13:00–14:00 Optional lunch

Departures

STEERING COMMITTEE


Jana Haberlová, MD, PhD

Motol University Hospital
Prague, Czech Republic

 

Aviva Fattal-Valevski, MD
Sackler Faculty of Medicine
Tel Aviv University and
Dana Dwek Children’s Hospital
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel

Katarzyna Kotulska-Jóźwiak, MD, PhD
The Children’s Memorial Health Institute
Warsaw, Poland

 

 

FACULTY

Elaine Chan, MD
Elena Mazzone, PT
Laurent Servais, MD, PhD

 

Disclosures of conflicts of interest

 

STEERING COMMITTEE
Jana Haberlová, MD, PhD
Dr. Haberlova has nothing to disclose.

Aviva Fattal-Valevski, MD
Dr. Fattal-Valevski has disclosed that she is/was a recipient of grants/research support from Biogen Inc., Novartis Gene Therapies (formerly AveXis), Shire plc, Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd. She is/was a recipient of consultation fees from Biogen Inc., Novartis Gene Therapies (formerly AveXis) and Takeda Pharmaceutical Company Limited.

Katarzyna Kotulska-Jóźwiak, MD, PhD
Dr. Kotulska-Jóźwiak has disclosed that she is/was a recipient of consultation fees from Biogen Inc., Novartis International AG and F. Hoffmann-La Roche AG.

 

FACULTY
Elaine Chan, MD
TBC

Elena Mazzone, PT
Elena Mazzone has disclosed that she is/was a recipient of consultation fees from Biogen Inc., F. Hoffmann-La Roche AG, Novartis Gene Therapies and Scholar Rock.

Laurent Servais, MD, PhD
Dr. Servais has disclosed that he is/was a recipient of grants/research from Biogen Inc., F-Hoffmann-La Roche AG and Novartis Gene Therapies, and that he is/was a recipient of consultation fees from Biogen Inc., BioHaven, F. Hoffmann-La Roche AG, Novartis Gene Therapies and Scholar Rock. Dr. Servais has disclosed that he participated in a company sponsored speakers’ bureau for Biogen Inc., F-Hoffmann-La Roche AG and Novartis Gene Therapies.

 

PLANNERS AND MANAGERS
Ology Medical Education planners and managers have nothing to disclose.

An application for accreditation has been submitted to UEMS-EACCME® for 10.0 ECMEC® credits.

DISCLAIMER
This event was organized to promote the exchange and dissemination of scientific and medical information only, with no promotional activity permitted. The views expressed during each presentation are those of the speaker only, and do not necessarily reflect the views of the organizers or sponsors. The presentations may discuss therapeutic products that have not been approved, or off-label use of certain products. All content is provided for general educational purposes only and should not in any way be considered as advisory. It is the responsibility of the healthcare professional to verify all information and data before treating patients or using any therapies described. All presentations are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) any part of the material presented, you must obtain all the necessary permissions from the publisher, original author, and any other current copyright owner.

This programme has been made possible thanks to an unrestricted independent educational grant received from Novartis Gene Therapies (formerly AveXis).

Please register here for the SMA Expert Exchange: Novel treatments in clinical practice meeting.

There is no registration fee for this meeting. Travel (economy round-trip flights and transfer to meeting venue from the airport) and accommodation for two nights will be organized for all participants by Ology Medical Education.

Any alternative travel arrangements and incidental costs made by the participants will not be reimbursed. Following your registration, you will be contacted by the organizers for further details so that we can arrange your travel.

EDUCATIONAL PARTNER
Ology Medical Education
info@ologyeducation.org

SMA Expert Exchange: Novel treatments in clinical practice
9 & 10 September 2022 in Prague, Czech Republic
UEMS accredited expert meeting
This activity is supported by an independent educational grant from Novartis Gene Therapies.

Register

Related activities